A Phase 4 interventional study of Gelatin 500 mL and Gelatin 50 mL in Anesthesia, sponsored by Hopital Foch. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-31.
Sponsored by Hopital Foch · Phase 4, Interventional, and Prevention
Induction of general anesthesia induces frequently arterial hypotension. The short term goal of this study is to evaluate if preemptive volume loading prevents such complication.
This is a randomized, prospective study which will include a total of 200 patients who are scheduled to undergo elective surgery. The research participants will be randomly assigned to
Volume loading is preceded by the measurement of stroke volume and cardiac output before and after a passive leg elevation test and followed by a standardized anesthetic protocol.
1,003 studies on the registry are indexed under Hypotension; 173 are open to participants now.
This study's enrollment of 17 is below the median of 80 across 675 interventional studies indexed under Hypotension.
Browse Hypotension studies →Hopital Foch is the lead sponsor of 208 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Gelatin 500 mL
Drug: Gelatin 50 mL
intravenous administration
intravenous administration
Hypotension
mean arterial pressure less than 70% of the baseline measurement
Time frame: 30 minutes
hemodynamic effect of leg passive elevation test
Time frame: 30 minutes
hemodynamic effect of volume loading
Time frame: 30 minutes
heart rate monitoring
Time frame: 30 minutes
propofol dose when bispectral index is 50
Time frame: 30 minutes
propofol site effect concentration when bispectral index is 50
Time frame: 30 minutes
arterial pressure monitoring
Time frame: 30 minutes
This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hopital Foch